Cell Source, Inc.
CLCS · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.26 | 0.49 | 1.09 | 0.00 |
| FCF Yield | -18.32% | -16.35% | -10.60% | -9.39% |
| EV / EBITDA | -6.84 | -5.59 | 0.00 | -455.53 |
| Quality | ||||
| ROIC | 44.09% | -0.00% | 88.27% | 119.73% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.56 | 0.44 | 0.61 | 0.62 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -14.32% | 25.20% | 7.10% | -21.77% |
| Safety | ||||
| Net Debt / EBITDA | -2.77 | -2.19 | 0.00 | -68.56 |
| Interest Coverage | -3.29 | -4.12 | -4.21 | -2.95 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |